Find Clinical Drug Pipelines for Sleep

Lead Product(s): Reboxetine

Therapeutic Area: Sleep

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Axsome Therapeutics

Deal Size: $331.0 million Upfront Cash: $3.0 million

Deal Type: Licensing Agreement January 13, 2020

Details:

Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which xpands Axsome’s pipeline with new Phase 3-stageesreboxetine product candidate for fibromyalgia

Lead Product(s): JZP-258

Therapeutic Area: Sleep

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

The submission is based on a Phase 3 global randomized-withdrawal, multicenter study that demonstrated the efficacy and safety of JZP-258 in the treatment of narcolepsy.

Lead Product(s): Mazindol

Therapeutic Area: Sleep

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: NLS Pharmaceutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 13, 2020

Details:

NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.